SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

US and European stock markets stalled or trimmed gains on Friday after a bullish week buoyed by US data and upbeat company ...

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s ...

The US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...

European and Asian stocks markets closed out the week broadly higher Friday following Wall Street's latest record highs ...